ICBMT 2025

Scientific Program

[PL01] Plenary Session 1 September 11 (Thu), 10:30-11:50		Room A
Chair(s)	TBD

10:30-11:10

T Cell Function and Dysfunction in Allo-SCT and GVHD

Warren Shlomchik

University of Pittsburgh, USA

CV
11:10-11:50

Optimization of Hematopoietic Stem Cell Transplantation using Drugs and Cellular Therapies

Hyoung Jin Kang

Seoul National University College of Medicine, Korea

Abstract

[PL02] Plenary Session 2 September 11 (Thu), 13:00-14:20		Room A
Chair(s)	TBD

13:00-13:40

New Concepts and Future Perspectives of CAR T-cell Therapy for Hematologic Malignancy

Peihua Lu

Lu Daopei Hospital, China

CV
13:40-14:20

Post-Transplantation Cyclophosphamide: From Revolution to Evolution in Allogeneic HSCT

Leo Luznik

Johns Hopkins Hospital, USA

[JS01] Joint Symposium 1 (ASTCT-KSBMT): Real-world Experiences in Optimization of Conditioning Regimen and GVHD Prophylaxis September 11 (Thu), 14:30-16:00		Room A
Chair(s)	TBD

14:30-15:00

Conditioning Intensity and the Role of TBI: Disease Control vs. GVHD Risk

Ryotaro Nakamura

City of Hope National Medical Center, USA

CV
15:00-15:30

Optimization of Donor and GVHD Prophylaxis with New Agents in the PTCY Era

Stefan O. Ciurea

University of California, Irvine, USA

CV
15:30-16:00

Optimization of Conditioning Regimens for Acute Leukemia in Korea

TBD

[SS01] Scientific Session 1: Innovative Cell & Gene Therapy September 11 (Thu), 14:30-16:00		Room B
Chair(s)	TBD

14:30-15:00

In vivo CAR-T Cell Generation

Byoung Ryu

Legend Biotech, USA

CV
15:00-15:30

Cancer Immunotherapy by γδ T Cells

Lawrence S. Lamb, Jr.

IN8Bio, Inc., USA

Abstract CV
15:30-16:00

Enhancing CAR-T/-NK Therapies by Mitigating Trogocytosis and Promoting Serial Killing

Duck Cho

Sungkyunkwan University School of Medicine, Korea

CV

[SS02] Scientific Session 2: Considerations for Optimal Allogeneic HSCT: Donor Age and Reducing Risk of Graft Failure September 11 (Thu), 14:30-16:00		Room C
Chair(s)	TBD

14:30-15:00

HSCT Guidelines for Aplastic Anemia: Optimizing Strategies in the Era of Novel Agents

Austin Kulasekararaj

King's College Hospital NHS Foundation Trust, UK

Abstract CV
15:00-15:30

Treatment of Patients with Donor-specific Anti-HLA Antibodies

Piyanuch Kongtim

University of California, Irvine, USA

CV
15:30-16:00

The Effect of Donor Age on HSCT Outcomes

Ji Eun Jang

Yonsei University College of Medicine, Korea

CV

[ES01] Education Session 1: Advances in Transplantation Practice September 11 (Thu), 14:30-16:00		Room D
Chair(s)	TBD

14:30-15:00

MRD Monitoring after HSCT

Saeam Shin

Yonsei University College of Medicine, Korea

Abstract CV
15:00-15:30

Optimizing Peripheral Blood Stem Cell Mobilization and Collection

Gi June Min

College of Medicine, The Catholic University of Korea, Korea

CV
15:30-16:00

Epstein-Barr virus-associated Lymphoma: Current Understanding and Treatment Strategies

Hee Young Ju

Sungkyunkwan University School of Medicine, Korea

CV

[JS02] Joint Symposium 2 (EBMT-KSBMT): The New Era of CAR-T Cell Therapy September 11 (Thu), 16:40-18:20		Room A
Chair(s)	TBD

16:40-17:05

CART Cell Therapy in RR B-ALL

Sebastian Giebel

Maria Sklodowska-Curie National Research Institute of Oncology, Poland

CV
17:05-17:30

CART Cell Therapy in B-cell Lymphoma

TBD
17:30-17:55

Current Status of CAR-T and Experiences in Korea

Sang Eun Yoon

Sungkyunkwan University School of Medicine, Korea

Abstract CV
17:55-18:20

Post CAR-T Allogeneic HCT in Korea

Jae Wook Lee

College of Medicine, The Catholic University of Korea, Korea

CV

[SS03] Scientific Session 3: Advancing Hematology through AI and Big Data: From Research to Clinical Application September 11 (Thu), 16:40-18:10		Room B
Chair(s)	TBD

16:40-17:10

Transforming Hematopathology: AI-Driven Insights into Myeloproliferative Neoplasm

Daniel Royston

University of Oxford, UK

CV
17:10-17:40

Artificial Intelligence in Hematology and Oncology

Jan-Niklas Eckardt

University Hospital Dresden, Germany

CV
17:40-18:10

Application of Large Language Models in Hematology Research and Scientific Writing

Sang-Hyun Hwang

University of Ulsan College of Medicine, Korea

CV

[SS04] Scientific Session 4: Understanding and Targeting Clonal Hematopoiesis September 11 (Thu), 16:40-18:10		Room C
Chair(s)	TBD

16:40-17:10

Therapeutic Targeting of Clonal Hematopoiesis

Steven Chan

University of Toronto, Canada

Abstract CV
17:10-17:40

Selenoprotein-mediated Redox Regulation Shapes the Cell Fate of HSCs and Mature Lineages

Daichi Inoue

The University of Osaka, Japan

CV
17:40-18:10

Role of Clonal Hematopoiesis in Cancer - Paracrine Effect

Youngil Koh

Seoul National University College of Medicine, Korea

CV

[JS03] Joint Symposium 3 (East Asia Collaborative Session): Stem Cell Transplantation in Diffuse Large B-cell Lymphoma in the Era of Immunotherapy September 12 (Fri), 10:10-11:50		Room A
Chair(s)	TBD

10:10-10:35

Optimizing Autologous Stem Cell Transplantation in the Age of CAR T-cell Therapy: Still a Standard?

Jieun Uhm

Hanyang University College of Medicine, Korea
10:35-11:00

Treatment Options after CAR T-cell Failure in Diffuse Large B-cell Lymphoma

Shinichi Makita

National Cancer Center Hospital, Japan
11:00-11:25

Integration of Stem Cell Transplant, CAR T-cell, and Next-generation Immunotherapies in High-grade B-cell Lymphoma

TBD
11:25-11:50

Immune Reconstitution after CAR T-cell Therapy vs. Stem Cell Transplantation: Mechanistic Insights and Clinical Implications

Tai-Chung Huang

National Taiwan University Hospital, Taiwan

CV

[SS05] Scientific Session 5 (KAICET-Cell Therapy Committee Joint Session): Next-Generation Immune Cell Therapies: From Design to Clinical Application September 12 (Fri), 10:10-11:40		Room B
Chair(s)	TBD

10:10-10:40

Development of Armored CAR-T Cell Therapeutics for Solid Tumors

Hyung Cheol Kim

Curocell Inc., Korea

CV
10:40-11:10

Immune Synapse Potentiating Novel CAR Structure-based Anti-CD19 CAR T Cells

Eun Young Choi

Seoul National University College of Medicine, Korea
11:10-11:40

From Bench to Bedside: The Promise of Engineered NK Cell Therapy

Katy Rezvani

The University of Texas MD Anderson Cancer Center, USA

Abstract CV

[SS06] Scientific Session 6: GVHD Update: Evolving Paradigms in Diagnosis and Therapy September 12 (Fri), 10:10-11:40		Room C
Chair(s)	TBD

10:10-10:40

Clinical Approach of GvHD Bronchiolitis Obliterans Syndrome - Focusing on Early Detection, Diagnosis, Treatment Approach

Guang-Shing Cheng

University of Washington School of Medicine, USA

CV
10:40-11:10

Emerging Therapies in GVHD and Future Direction (GVHD Treatment Paradigms: Promising Agents Nearing Clinical Use)

Corey Cutler

Dana-Farber / Harvard Cancer Center, USA

CV
11:10-11:40

Novel Therapies for Chronic GVHD

Robert Zeiser

University Medical Center Freiburg, Germany

Abstract CV

[ES02] Education Session 2: Smart Research Practices: From Data Analysis to Writing September 12 (Fri), 10:10-11:40		Room D
Chair(s)	TBD

10:10-10:40

Medical Research and Scientific Writing using AI

Yohan Koo

CHA University, Korea
10:40-11:10

Scientific Writing in BMT and Cellular Therapy Research

Mohamad Mohty

Saint-Antoine Hospital, France

CV
11:10-11:40

Application of R Statistics in HSCT Research (EZR)

Yoshinobu Kanda

Jichi Medical University, Japan

CV

[SS07] Scientific Session 7: Transplantation and Relapse: Evidence and Practice Updates September 12 (Fri), 13:00-14:30		Room A
Chair(s)	TBD

13:00-13:30

Donor Lymphocyte Infusion Strategy: Korean Institutional Perspective

Silvia Park

College of Medicine, The Catholic University of Korea, Korea
13:30-14:00

Strategies to Reduce Relapse after HSCT in ALL Patients

Partow Kebriaei

The University of Texas MD Anderson Cancer Center, USA

CV
14:00-14:30

Next-Generation Therapeutics: Gene Therapy Strategies for Refractory Hematologic Cancers

TBD

[SS08] Pediatric September 12 (Fri), 13:00-14:30		Room B
Chair(s)	TBD

13:00-13:30

Allogeneic CAR T-cell Therapies

TBD
13:30-14:00

The Optimal Conditioning for Allo-HSCT in Children with ALL (FORUM Trial)

Krzysztof Kalwak

Wroclaw Medical University, Poland

CV
14:00-14:30

Management of Post-HSCT Relapse in Pediatric Leukemia

Jae Won Yoo

College of Medicine, The Catholic University of Korea, Korea

[NS01] Nursing Session 1: Multidisciplinary Approach to Treatment after Hematopoietic Stem Cell Transplantation l (KOR.) September 12 (Fri), 13:00-14:30		Room C
Chair(s)	EunJung Joo (National Cancer Center, Korea)

13:00-13:30

Optimizing Endocrine Outcomes after Hematopoietic Stem Cell Transplantation

Daham Kim

Yonsei University College of Medicine, Korea

CV
13:30-14:00

Acute Kidney Injury after Hematopoietic Stem Cell Transplantation

Junseok Jeon

Sungkyunkwan University School of Medicine, Korea

CV
14:00-14:30

Psychosocial Distress in Hematopoietic Stem Cell Transplantation

Eun-Seung Yu

The Cyber University of Korea, Korea

[ES03] Education Session 3: Optimizing Outcomes in HSCT September 12 (Fri), 13:00-14:30		Room D
Chair(s)	TBD

13:00-13:30

Intensity of Conditioning Regimen (Evolution of Conditioning Regimen)

Yong Park

Korea University College of Medicine, Korea
13:30-14:00

Advances in GVHD Prophylaxis: From ATG to Post-Transplant Cyclophosphamide (PTCy)

Joon Ho Moon

Kyungpook National University School of Medicine, Korea
14:00-14:30

Second Malignancy after HSCT

Daehun Kwag

College of Medicine, The Catholic University of Korea, Korea

[PS01] Presidential Symposium September 12 (Fri), 14:40-15:20		Room A
Chair(s)	TBD

14:40-15:20

AML-Specific Therapeutics: Integrating Risk-Stratified Transplantation and Immunotherapeutic Targeting

Soheil Meshinchi

Fred Hutchinson Cancer Center, USA

CV

[PL03] Plenary Session 3 September 12 (Fri), 15:20-16:00		Room A
Chair(s)	TBD

15:20-16:00

Personalized Conditioning Strategies in Allogeneic HSCT: Balancing Disease Control and Toxicity Across Age Groups

Mohamad Mohty

Saint-Antoine Hospital, France

CV

[DS01] Debate Session 1: Splenectomy Prior to HSCT in in Myelofibrosis: Necessity or Risk? September 12 (Fri), 16:40-18:20		Room A
Chair(s)	TBD

16:40-16:55

Necessity

Ik-Chan Song

Chungnam National University College of Medicine, Korea

CV
16:55-17:10

Risk

Yunsuk Choi

University of Ulsan College of Medicine, Korea

[DS02] Debate Session 2: Donor Selection for HSCT in Pediatric Leukemia: Haploidentical versus Other Alternative Donor September 12 (Fri), 16:40-18:20		Room A
Chair(s)	TBD

17:30-17:45

Haploidentical

Sung Han Kang

University of Ulsan College of Medicine, Korea
17:45-18:00

Other Alternative Donor

Kyung Taek Hong

Seoul National University College of Medicine, Korea

CV

[JS04] Joint Symposium 4 (JSTCT-KSBMT): Transplant Strategies to Overcome MRD Positive Hematologic Malignancies September 12 (Fri), 16:40-18:20		Room C
Chair(s)	TBD

16:40-17:05

Inter-methodological Discrepancies and a Definition of MRD Response

TBD
17:05-17:30

Transplantation & Management of High-risk ALL with Poor MRD Response

Yu Akahoshi

National Cancer Center Hospital, Japan

CV
17:30-17:55

Integrating Flow Cytometry-Based MRD into Transplant and Maintenance Strategies in MM

Ari Ahn

College of Medicine, The Catholic University of Korea, Korea

CV
17:55-18:20

Transplantation & Management of High-risk MM with Poor MRD Response

Hyunsoo Cho

Yonsei University College of Medicine, Korea

CV

[ES04] Education Session 4: Infectious Complication September 12 (Fri), 16:40-18:10		Room D
Chair(s)	TBD

16:40-17:10

Viral Infection after HSCT

Seung-Ji Kang

Chonnam National University Medical School, Korea
17:10-17:40

Infection Prophylaxis in CAR T Cell Therapy

Ji Hyun Lee

Dong-A University Hospital, Korea
17:40-18:10

Should a Well-Cooked Diet Be Recommended for Transplant Patients?

Annalisa Paviglianiti

Hospital de la Santa Creu i Sant Pau, Spain

CV

[JS05] Joint Symposium 5 (ISCT-KSBMT): Bridging Cell Therapy and Hematopoietic Stem Cell Transplantation September 13 (Sat), 09:00-10:30		Room A
Chair(s)	TBD

09:00-09:30

Going Beyond Conventional CAR T Cell Therapies for Treatment of Blood Cancer and Other Diseases

William Hwang

Duke-NUS Medical School, Singapore

CV
09:30-10:00

Virus-Specific T-Cell Therapy: The Ultimate Weapon in the Endless Battle Against Post-Transplant Viral Infections

Seok-Goo Cho

College of Medicine, The Catholic University of Korea, Korea

CV
10:00-10:30

MSC Treatment in HSCT and GVHD

TBD

[SS09] Scientific Session 9: Navigating Critical HSCT Complications September 13 (Sat), 09:00-10:30		Room C
Chair(s)	TBD

09:00-09:30

Diagnostic Imaging for Sinusoidal Obstruction Syndrome (SOS), including the Use of Liver Elastography

Souichi Shiratori

Hokkaido University Faculty of Medicine, Japan

CV
09:30-10:00

Diagnosis and Management of TA-TMA

Sonata Jodele

Cincinnati Children’s Hospital Medical Center, USA

CV
10:00-10:30

Post-HSCT Viral Management: Strategies Beyond the Guidelines

Raeseok Lee

College of Medicine, The Catholic University of Korea, Korea

CV

[SS10] Scientific Session 10: Immunotherapy and Transplantation in Myeloid Malignancies: Evolving Strategies and Clinical Advances September 13 (Sat), 09:00-10:30		Room D
Chair(s)	TBD

09:00-09:30

Evolving Paradigms in AML: How Transplantation Fits in the Modern Therapeutic Landscape

Musa Yilmaz

The University of Texas MD Anderson Cancer Center, USA

CV
09:30-10:00

Immune Checkpoint Modulation in Myeloid Malignancies: Will We Find Success Soon?

Amer M. Zeidan

Yale Cancer Center, USA

CV
10:00-10:30

Augmenting NK-cell Immunity for the Treatment of Myeloid Malignancies using Hypomethylating Agents

Junshik Hong

Seoul National University College of Medicine, Korea

CV

[JS06] Joint Symposium 6 (TSBMT-KSBMT): Chronic GVHD or Rare Transplantation Related Complications September 13 (Sat), 10:40-11:40		Room A
Chair(s)	TBD

10:40-11:10

Pathophysiology and Management of Chronic GVHD

TBD
11:10-11:40

Rare Transplantation-related Cardiac or Neurological Complications

Jin Kyung Suh

University of Ulsan College of Medicine, Korea

[SS11] Scientific Session 11: Maximizing MM Treatment: Integrating Transplantation, Maintenance, and Novel Immunotherapies September 13 (Sat), 10:40-12:10		Room C
Chair(s)	TBD

10:40-11:10

Do We Need ASCT for MM Patients in the New Agent Era?

Thierry Facon

Lille University Hospital, France

CV
11:10-11:40

Autologous NK Cell Therapy as a Consolidative Strategy after Auto-SCT

Evren Alici

Karolinska University Hospital, Sweden

CV
11:40-12:10

The Role of Salvage Auto-HSCT in RRMM Patients

Jongheon Jung

National Cancer Center, Korea

[NS02] Nursing Session 2: Multidisciplinary Approach to Treatment after Hematopoietic Stem Cell Transplantation ll (KOR.) September 13 (Sat), 10:40-11:40		Room D
Chair(s)	Heejun Kim (Samsung Medical Center, Korea)

10:40-11:10

How Can We Reduce Liver-related Morbidity and Mortality in Patients after HSCT?

Pil Soo Sung

College of Medicine, The Catholic University of Korea, Korea

CV
11:10-11:40

Practical Oral Care for HSCT

Jusik Kim

Seoul National University College of Medicine, Korea

CV